Genome-wide 5-Hydroxymethylcytosine Profiling Analysis Identifies MAP7D1 As A Novel Regulator of Lymph Node Metastasis in Breast Cancer.

Shuang-Ling Wu,Xiaoyi Zhang,Mengqi Chang,Changcai Huang,Jun Qian,Qing Li,Fang Yuan,Lihong Sun,Xinmiao Yu,Xinmiao Cui,Jiayi Jiang,Mengyao Cui,Ye Liu,Huan-Wen Wu,Zhi-Yong Liang,Xiaoyue Wang,Yamei Niu,Wei-Min Tong,Feng Jin

DOI: https://doi.org/10.1016/j.gpb.2019.05.005

2021-01-01

Abstract:Although DNA 5-hydroxymethylcytosine (5hmC) is recognized as an important epigenetic mark in cancer, its precise role in lymph node metastasis remains elusive. In this study, we investigated how 5hmC associates with lymph node metastasis in breast cancer. Accompanying with high expression of TET1 and TET2 proteins, large numbers of genes in the metastasis-positive primary tumors exhibit higher 5hmC levels than those in the metastasis-negative primary tumors. In contrast, the TET protein expression and DNA 5hmC decrease significantly within the metastatic lesions in the lymph nodes compared to those in their matched primary tumors. Through genome-wide analysis of 8 sets of primary tumors, we identified 100 high-confidence metastasis-associated 5hmC signatures, and it is found that increased levels of DNA 5hmC and gene expression of MAP7D1 associate with high risk of lymph node metastasis. Furthermore, we demonstrate that MAP7D1, regulated by TET1, promotes tumor growth and metastasis. In conclusion, the dynamic 5hmC profiles during lymph node metastasis suggest a link between DNA 5hmC and lymph node metastasis. Meanwhile, the role of MAP7D1 in breast cancer progression suggests that the metastasis-associated 5hmC signatures are potential biomarkers to predict the risk for lymph node metastasis, which may serve as diagnostic and therapeutic targets for metastatic breast cancer.